Whole-Genome Sequencing Is Here, But Clinical Utility Remains Unproven
This article was originally published in The Gray Sheet
Executive Summary
Multiple firms are racing to develop an affordable whole-genome sequencing product as a marketable diagnostics tool, but clinicians and genetics experts told a government advisory panel last week that the practice is not yet ready for clinical application